Protalix BioTherapeutics, Inc.
PLX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001006281
No open-market purchases or sales by Protalix BioTherapeutics, Inc. insiders were filed in the last 90 days; 101 institutions reported holding it in 13F filings for Q2 2026, worth $33.7M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Protalix BioTherapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 34 | 66 | +32 |
| Shares | 2.94M | 8.98M | +6.04M (+205.5%) |
| Value | $6.15M | $17.9M | +$11.8M (+191.3%) |
New holders (39)
Institutions that held Protalix BioTherapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
Sold out (7)
Institutions that held Protalix BioTherapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Meitav Dash Investments Ltd | 244,332 | $493.6K |
| Citadel Advisors LLC | 211,548 | $444.3K |
| CIBC World Markets Inc. | 25,000 | $52.0K |
| Two Sigma Advisers, LP | 19,900 | $41.8K |
| HRT Financial LP | 10,309 | $21.0K |
| Federated Hermes, Inc. | 5,761 | $12.1K |
| Psagot Value Holdings Ltd. / (Israel) | 3,744 | $7.00K |